[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"HUMAN MED AG\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":57},{"warningLetters":4,"total":56},[5,33],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":31,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},1567,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-03-12T13:20:00Z\">03\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-02-09T05:00:00Z\">02\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhuman-microbes-672740-02092024\">Human Microbes\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","CGMP\u002FDeviations\u002FBiologics License Application (BLA)\u003Cbr \u002F>\r\n","","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail \n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-672740\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael J. Harrop\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Human Microbes\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3870 La Sierra Avenue #1069\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Riverside\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92505\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:michael@humanmicrobes.org\"> michael@humanmicrobes.org\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #CBER-24-672740\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: February 09, 202\u003Cbr>\n\u003Cbr>\nDear Mr. Harrop:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.humanmicrobes.org in February 2024, which contains instructions on how to buy fecal microbiota for transplantation (FMT) (hereinafter, “your products”). Your website indicates that you are offering for sale (in the United States, Canada, and other parts of the world) FMT in various forms (e.g., capsules, enemas, and infusions) for the treatment or prevention of various diseases or conditions. For example, your website states the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“FMT is a lifesaving treatment for the deadly gut infection Clostridium Difficile (C. Diff) and has shown promising results in clinical trials for many other conditions [1], such as IBS (\u003Cem>irritable bowel syndrome\u003C\u002Fem>), IBD (\u003Cem>inflammatory bowel disease\u003C\u002Fem>), Parkinson’s disease, fibromyalgia, chronic fatigue syndrome (CFS), multiple sclerosis, autism, diabetes, and mental health disorders like depression, anxiety, and bipolar.”\u003C\u002Fli>\n\t\u003Cli>“FMT may also have potential applications in the treatment of obesity, autoimmunity, cardiovascular disease, cancer, and more.”\u003C\u002Fli>\n\t\u003Cli>“FMT is also a treatment option to attenuate adverse effects associated with antibiotic use.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your YouTube channel (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=jPRg-_voHXQ) has a video titled, “We want your poop” that contains the following statements:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“FMTs offer a potential new treatment option for a long list of conditions…including irritable bowel syndrome, obesity and even mental disorders.”\u003C\u002Fli>\n\t\u003Cli>Refers to a patient “cured her bipolar disorder after receiving an FMT”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Because these statements indicate that your products are intended for use in the mitigation, treatment, or prevention of disease, they are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)]. Your products are also “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective (GRASE) for their labeled uses. Additionally, your products are biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because they are applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. A biological product for which a BLA has been approved under 42 U.S.C. § 262(a) is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in 21 U.S.C. § 355(a). While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your products are not the subject of an approved BLA or an approved application under 21 U.S.C. § 355. In addition, there is no IND in effect for their use. Therefore, your products are both unapproved new drugs and unlicensed biological products. Furthermore, based on the statements on your website, you cause the introduction or delivery for introduction into interstate commerce of your products in violation of the FD&amp;C Act [21 U.S.C. § 331(d)].\u003C\u002Fp>\n\n\u003Cp>We note that your website references an “FDA enforcement discretion policy” regarding FMT. In November 2022, FDA issued a revised guidance titled, “\u003Cu>Enforcement Policy Regarding Investigational New Drugs Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridioides difficile Infection Not Responsive to Standard Therapies\u003C\u002Fu>”. This guidance document indicates that FDA intends to exercise enforcement discretion regarding the IND requirements for the use of FMT in treating \u003Cem>Clostridioides difficile (C. difficile)\u003C\u002Fem> infection not responding to standard therapies, where, among other things, the stool donor and stool are qualified by screening and testing performed under the direction of the licensed health care provider for the purpose of providing the FMT product to treat his or her patient and use of the FMT product does not raise reported safety concerns or potential significant safety concerns.\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, you offer FMT for treatment of diseases and conditions other than \u003Cem>C. difficile\u003C\u002Fem> infection. As noted in FDA’s November 2022 guidance, data related to the use and study of FMT to treat diseases or conditions other than \u003Cem>C. difficile\u003C\u002Fem> infection not responding to standard therapies are more limited, and study of FMT for other uses is not included in the aforementioned enforcement policy. In addition, although your website recommends that patients “discuss their plans with their doctor,” it offers your products directly to patients, including for self-administration. For example, your website indicates that donors can ship your products directly to patients and provides instructions on methods of self-administration. Therefore, there is no assurance that a licensed health care provider treating each of these patients is directing the screening and testing of the stool donor and stool for the patient, as described in the November 2022 guidance. Your products also raise potential significant safety concerns due to inadequate donor screening. We also note the reported safety concerns described in the “donor results spreadsheet” on your website (e.g., “increased intestinal pain, nausea, sweating, and loss of appetite among other things”). For these reasons, your products would not fall within the enforcement discretion policy referenced above.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your products are not in violation of the FD&amp;C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FMT is a live biotherapeutic product composed of microorganisms. Microorganisms are not human cells or tissues and do not meet the definition of HCT\u002FP (see 21 CFR 1271.3(d)).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER-24-672740\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMichael J. Harrop\n\nRecipient Title\n\nFounder\n\nHuman Microbes\n\n3870 La Sierra Avenue #1069\n\nRiverside, CA 92505\n\nUnited States\n\nmichael@humanmicrobes.org\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nWarning Letter #CBER-24-672740\n\nDate: February 09, 202\n\nDear Mr. Harrop:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at www.humanmicrobes.org in February 2024, which contains instructions on how to buy fecal microbiota for transplantation (FMT) (hereinafter, “your products”). Your website indicates that you are offering for sale (in the United States, Canada, and other parts of the world) FMT in various forms (e.g., capsules, enemas, and infusions) for the treatment or prevention of various diseases or conditions. For example, your website states the following:\n\n“FMT is a lifesaving treatment for the deadly gut infection Clostridium Difficile (C. Diff) and has shown promising results in clinical trials for many other conditions [1], such as IBS (irritable bowel syndrome), IBD (inflammatory bowel disease), Parkinson’s disease, fibromyalgia, chronic fatigue syndrome (CFS), multiple sclerosis, autism, diabetes, and mental health disorders like depression, anxiety, and bipolar.”\n\n“FMT may also have potential applications in the treatment of obesity, autoimmunity, cardiovascular disease, cancer, and more.”\n\n“FMT is also a treatment option to attenuate adverse effects associated with antibiotic use.”\n\nAdditionally, your YouTube channel (https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=jPRg-_voHXQ) has a video titled, “We want your poop” that contains the following statements:\n\n“FMTs offer a potential new treatment option for a long list of conditions…including irritable bowel syndrome, obesity and even mental disorders.”\n\nRefers to a patient “cured her bipolar disorder after receiving an FMT”\n\nBecause these statements indicate that your products are intended for use in the mitigation, treatment, or prevention of disease, they are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 321(g)(1)(B)]. Your products are also “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective (GRASE) for their labeled uses. Additionally, your products are biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. § 262(i)] because they are applicable to the prevention, treatment, or cure of a disease or condition of human beings.1\n\nPlease be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. A biological product for which a BLA has been approved under 42 U.S.C. § 262(a) is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in 21 U.S.C. § 355(a). While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312]. Your products are not the subject of an approved BLA or an approved application under 21 U.S.C. § 355. In addition, there is no IND in effect for their use. Therefore, your products are both unapproved new drugs and unlicensed biological products. Furthermore, based on the statements on your website, you cause the introduction or delivery for introduction into interstate commerce of your products in violation of the FD&C Act [21 U.S.C. § 331(d)].\n\nWe note that your website references an “FDA enforcement discretion policy” regarding FMT. In November 2022, FDA issued a revised guidance titled, “Enforcement Policy Regarding Investigational New Drugs Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridioides difficile Infection Not Responsive to Standard Therapies”. This guidance document indicates that FDA intends to exercise enforcement discretion regarding the IND requirements for the use of FMT in treating Clostridioides difficile (C. difficile) infection not responding to standard therapies, where, among other things, the stool donor and stool are qualified by screening and testing performed under the direction of the licensed health care provider for the purpose of providing the FMT product to treat his or her patient and use of the FMT product does not raise reported safety concerns or potential significant safety concerns.\n\nBased on a review of your website, you offer FMT for treatment of diseases and conditions other than C. difficile infection. As noted in FDA’s November 2022 guidance, data related to the use and study of FMT to treat diseases or conditions other than C. difficile infection not responding to standard therapies are more limited, and study of FMT for other uses is not included in the aforementioned enforcement policy. In addition, although your website recommends that patients “discuss their plans with their doctor,” it offers your products directly to patients, including for self-administration. For example, your website indicates that donors can ship your products directly to patients and provides instructions on methods of self-administration. Therefore, there is no assurance that a licensed health care provider treating each of these patients is directing the screening and testing of the stool donor and stool for the patient, as described in the November 2022 guidance. Your products also raise potential significant safety concerns due to inadequate donor screening. We also note the reported safety concerns described in the “donor results spreadsheet” on your website (e.g., “increased intestinal pain, nausea, sweating, and loss of appetite among other things”). For these reasons, your products would not fall within the enforcement discretion policy referenced above.\n\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\n\nWe advise you to comprehensively review your website and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your products are not in violation of the FD&C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\n_______________________\n\n1 FMT is a live biotherapeutic product composed of microorganisms. Microorganisms are not human cells or tissues and do not meet the definition of HCT\u002FP (see 21 CFR 1271.3(d)).","Human Microbes","human-microbes-672740-02092024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhuman-microbes-672740-02092024","2026-10-26T08:08:56.778732+00:00","Warning Letter","Issued","2024-03-12","672740","Biologics","Michael J. Harrop","2026-08-20T00:14:31.434+00:00","VIA UPS and Electronic Mail","CBER-24-672740","2024-02-09",{"id":34,"raw":35,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":24,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":20,"issuing_office":39,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":20,"reference_number":54,"action_taken_date":55,"medical_device_id":20,"response_letter_date":20},125,[36,37,38,39,40,13,13,13],"\u003Ctime datetime=\"2026-06-09T04:00:00Z\">06\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-03T04:00:00Z\">06\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhubei-gedian-humanwell-pharmaceutical-co-ltd-725591-06032026\">Hubei Gedian Humanwell Pharmaceutical Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-93\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Hailin Chen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Hubei Gedian Humanwell Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 25 Juxian Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gedian Economic Development District\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ezhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hubei Sheng\u003C\u002Fspan>, \u003Cspan>436070\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:chenhalin@renfu.com.cn\"> chenhalin@renfu.com.cn\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-93\u003C\u002Fp>\u003Cp>June 3, 2026\u003C\u002Fp>\u003Cp>Dear Dr. Chen:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Hubei Gedian Humanwell Pharmaceutical Co., Ltd., FEI 3004117486, located at No. 25 Juxian Road, Gedian Economic Development District, Ezhou City, Hubei Province, China, from November 3 to 7, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 28, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the U.S. market. During the inspection, our investigator observed numerous scratches and \u003Cstrong>(b)(4)\u003C\u002Fstrong> stains on the interior API-contact surfaces of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessels, as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> markings on the lid and rim of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessel. These markings and discolored stains indicate that the integrity of the API-contact surfaces is being compromised which can lead to contamination of your API with particulate matter (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles) or alter the quality of the API via chemical leachable reactions.\u003C\u002Fp>\u003Cp>In your response, you state that compatibility between the equipment product contact surface material of construction and the chemical process, specifically the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process, is insufficient. You state that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> chemicals used in the process weakens the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces which leads to \u003Cstrong>(b)(4)\u003C\u002Fstrong> manifested as \u003Cstrong>(b)(4)\u003C\u002Fstrong> stains\u002Fdiscoloration and scratches. You \u003Cstrong>(b)(4)\u003C\u002Fstrong> your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> the interior walls and plan to perform preventive \u003Cstrong>(b)(4)\u003C\u002Fstrong> maintenance \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You \u003Cstrong>(b)(4)\u003C\u002Fstrong> the \u003Cstrong>(b)(4)\u003C\u002Fstrong> markings on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and lid and replaced the \u003Cstrong>(b)(4)\u003C\u002Fstrong> gasket sealing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lid.\u003C\u002Fp>\u003Cp>Your response is inadequate because you do not support the frequency of your preventive \u003Cstrong>(b)(4)\u003C\u002Fstrong> maintenance schedule with scientific rationale based on your processes’ chemistry. Your response also did not evaluate the reactivity of all interior surfaces of the equipment train with your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process. Furthermore, you rationalized that the risk to product quality risk is low based on results of release testing using a qualified method.\u003C\u002Fp>\u003Cp>Your equipment materials of construction are inadequate because your product-contact surfaces may alter the quality of the product in that they were additive, absorptive, or reactive. Inadequately maintained manufacturing equipment can lead to potential contamination that could compromise the quality and safety of your APIs.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all batches within expiry that could have been affected by scratches and discoloration within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessels introduced as a result of your manufacturing process, including an evaluation of retain samples for elements within your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and\u002For impurities. Include a review of customer complaints for the last three years.\u003C\u002Fli>\u003Cli>A review of all your manufacturing processes to determine whether there is reactivity with all respective product-contact surfaces in your equipment.\u003C\u002Fli>\u003Cli>An evaluation of your process and equipment to determine whether changes will be implemented to remove the risk of foreign material introduced to APIs due to process design and inadequate product contact materials of construction. Include a list of all product contact surfaces exposed to varying chemical reactions in your facility, and supporting information regarding \u003Cstrong>(b)(4)\u003C\u002Fstrong> resistance against typical conditions in the vessels. Also include a plan, including timeline, for changing product contact surfaces to appropriate \u003Cstrong>(b)(4)\u003C\u002Fstrong> materials of construction given the inherent nature of the chemical processes utilized.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) was not exercising its basic responsibilities for oversight of the manufacture of your APIs. For example, your QU failed to ensure the following:\u003C\u002Fp>\u003Cul>\u003Cli>Buildings and facilities used in the manufacture of APIs have been properly maintained (e.g., no gaps around windows and doors).\u003C\u002Fli>\u003Cli>You did not evaluate the compatibility between the equipment product contact surface material of construction and the chemical processes used in the manufacture of APIs to ensure suitability for its intended use.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you revised the job responsibilities of the QU to increase the spot check frequency and to inspect the production floor equipment conditions. Your response is inadequate because the revised QU inspection duties checklist includes determining whether the equipment is “under normal working conditions.” This statement is vague and does not specify or provide appropriate guidance to identify discoloration, scratches, markings, and production room structural issues.\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An assessment of each drug product process to ensure suitability of equipment for its intended use and sufficiency of detectability in your monitoring and testing systems.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>API CGMP Guidance\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers the expectations outlined in International Conference on Harmonization (ICH) Q7 when determining whether APIs and intermediates are manufactured in conformance with CGMP. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of APIs at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA refusing admission of articles manufactured at Hubei Gedian Humanwell Pharmaceutical Co., Ltd., FEI 3004117486, located at No. 25 Juxian Road, Gedian Economic Development District, Ezhou City, Hubei Province, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004117486 and ATTN: Barbara Wilimczyk-Macri.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: Registered U.S. Agent\u003Cbr>Registrar Corp\u003Cbr>Email: drugs@registrarcorp.com\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-93\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Hailin Chen\n\nRecipient Title\n\nGeneral Manager\n\nHubei Gedian Humanwell Pharmaceutical Co., Ltd.\n\nNo. 25 Juxian Road\n\nGedian Economic Development District\n\nEzhou Shi\n\nHubei Sheng, 436070\n\nChina\n\nchenhalin@renfu.com.cn\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-93\nJune 3, 2026\nDear Dr. Chen:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Hubei Gedian Humanwell Pharmaceutical Co., Ltd., FEI 3004117486, located at No. 25 Juxian Road, Gedian Economic Development District, Ezhou City, Hubei Province, China, from November 3 to 7, 2025.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 28, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific deviations including, but not limited to, the following.\n1. Failure to clean equipment and utensils to prevent contamination or carry-over of a material that would alter the quality of the API beyond the official or other established specifications.\nYour firm manufactures (b)(4) for the U.S. market. During the inspection, our investigator observed numerous scratches and (b)(4) stains on the interior API-contact surfaces of your (b)(4) vessels, as well as (b)(4) markings on the lid and rim of the (b)(4) of your (b)(4) vessel. These markings and discolored stains indicate that the integrity of the API-contact surfaces is being compromised which can lead to contamination of your API with particulate matter (e.g., (b)(4) particles) or alter the quality of the API via chemical leachable reactions.\nIn your response, you state that compatibility between the equipment product contact surface material of construction and the chemical process, specifically the (b)(4) and the (b)(4) process, is insufficient. You state that the (b)(4) chemicals used in the process weakens the (b)(4) on the (b)(4) surfaces which leads to (b)(4) manifested as (b)(4) stains\u002Fdiscoloration and scratches. You (b)(4) your (b)(4) and (b)(4) the interior walls and plan to perform preventive (b)(4) maintenance (b)(4). You (b)(4) the (b)(4) markings on the (b)(4) and lid and replaced the (b)(4) gasket sealing the (b)(4) lid.\nYour response is inadequate because you do not support the frequency of your preventive (b)(4) maintenance schedule with scientific rationale based on your processes’ chemistry. Your response also did not evaluate the reactivity of all interior surfaces of the equipment train with your (b)(4) process. Furthermore, you rationalized that the risk to product quality risk is low based on results of release testing using a qualified method.\nYour equipment materials of construction are inadequate because your product-contact surfaces may alter the quality of the product in that they were additive, absorptive, or reactive. Inadequately maintained manufacturing equipment can lead to potential contamination that could compromise the quality and safety of your APIs.\nIn response to this letter, provide:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA retrospective, independent review of all batches within expiry that could have been affected by scratches and discoloration within the (b)(4) vessels introduced as a result of your manufacturing process, including an evaluation of retain samples for elements within your (b)(4) and\u002For impurities. Include a review of customer complaints for the last three years.\nA review of all your manufacturing processes to determine whether there is reactivity with all respective product-contact surfaces in your equipment.\nAn evaluation of your process and equipment to determine whether changes will be implemented to remove the risk of foreign material introduced to APIs due to process design and inadequate product contact materials of construction. Include a list of all product contact surfaces exposed to varying chemical reactions in your facility, and supporting information regarding (b)(4) resistance against typical conditions in the vessels. Also include a plan, including timeline, for changing product contact surfaces to appropriate (b)(4) materials of construction given the inherent nature of the chemical processes utilized.\n2. Failure of your quality unit to exercise its responsibility to ensure the API manufactured at your facility are in compliance with CGMP.\nYour quality unit (QU) was not exercising its basic responsibilities for oversight of the manufacture of your APIs. For example, your QU failed to ensure the following:\nBuildings and facilities used in the manufacture of APIs have been properly maintained (e.g., no gaps around windows and doors).\nYou did not evaluate the compatibility between the equipment product contact surface material of construction and the chemical processes used in the manufacture of APIs to ensure suitability for its intended use.\nIn your response, you state that you revised the job responsibilities of the QU to increase the spot check frequency and to inspect the production floor equipment conditions. Your response is inadequate because the revised QU inspection duties checklist includes determining whether the equipment is “under normal working conditions.” This statement is vague and does not specify or provide appropriate guidance to identify discoloration, scratches, markings, and production room structural issues.\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective management oversight of your production operations, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s global manufacturing operations to ensure that your systems, processes, and products conform to FDA requirements.\nIn response to this letter, provide:\nAn assessment of each drug product process to ensure suitability of equipment for its intended use and sufficiency of detectability in your monitoring and testing systems.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\nAPI CGMP Guidance\nFDA considers the expectations outlined in International Conference on Harmonization (ICH) Q7 when determining whether APIs and intermediates are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of APIs at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA refusing admission of articles manufactured at Hubei Gedian Humanwell Pharmaceutical Co., Ltd., FEI 3004117486, located at No. 25 Juxian Road, Gedian Economic Development District, Ezhou City, Hubei Province, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004117486 and ATTN: Barbara Wilimczyk-Macri.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCc: Registered U.S. Agent\nRegistrar Corp\nEmail: drugs@registrarcorp.com\n_______________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Hubei Gedian Humanwell Pharmaceutical Co., Ltd.","hubei-gedian-humanwell-pharmaceutical-co-ltd-725591-06032026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhubei-gedian-humanwell-pharmaceutical-co-ltd-725591-06032026","2026-10-26T08:08:56.566407+00:00","2026-06-09","725591","Drugs","Dr. Hailin Chen","2026-08-19T04:37:50.738+00:00","VIA UPS","320-26-93","2026-06-03",2,{"510k":58,"classification":59,"enforcement":60,"event":61,"event_backfill":62,"pma":63,"warning_letter":64},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]